Leap Therapeutics is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research.
View Latest Company Presentation
Our most advanced clinical programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and proliferate, known as cancer cell signaling, and pathways that enable body’s immune system to identify and attack cancer.
Successful leadership and development team, working together for over 20 years. Comprehensive experience acquiring and developing approved transformational therapies.
Therapies targeting cancer cell signaling and T cells may offer new options for patients with cancer.
